nnmt

NNMT-IN-4 (compound 38) is a selective, uncompetitive inhibitor of nicotinamide N-methyltransferase (NNMT) with in vitro biochemical and cell-based assay IC50 values of 42 nM and 38 nM, respectively. It demonstrates favorable pharmacokinetics pharmacodynamics (PK PD) and safety profiles, excellent oral bioavailability, and promising pharmaceutical properties. NNMT-IN-4 serves as an in vivo chemical probe for NNMT [1].

NNMT-IN-2 is a very potent inhibitor of NNMT (IC50: 3.7 nM).

NNMT-IN-3 (compound 14) is a potent and selective inhibitor of nicotinamide N-methyltransferase (NNMT), with IC50 values of 1.1 nM in cell-free assays and 0.4 μM in cell-based assays. NNMT-IN-3 can be utilized in studies of obesity, cancer, type II diabetes, and skeletal sarcopenia, among other diseases.

Bisubstrate Inhibitor 78 HCl is an NNMT inhibitor (IC50 = 1.41 μM) with potential anticancer activity, inhibiting the proliferation of HSC-2 oral cancer cells at 100 μM.

JBSNF-000088 is an Nicotinamide N-methyltransferase (NNMT)inhibitor. It is used for the treatment of metabolic disorders.

JBSNF-000028 is an orally active and potent nicotinamide N-methyltransferase (NNMT) inhibitor with inhibitory effects on human NNMT (hNNMT), monkey NNMT (mkNNMT), and mouse NNMT (mNNMT) with IC50s of 0.033 μM, 0.19 μM, and 0.21 μM, respectively.JBSNF-000028 can drive insulin sensitization and weight loss. 000028 drives insulin sensitization, glucose regulation and weight loss and can be used to study metabolic disorders.

Bisubstrate inhibitor 78 is an inhibitor of nicotinamide N-methyltransferase (NNMT; IC50= 1.41 μM).1It binds the NNMT active site in the binding pockets for the NNMT substrates S-adenosyl-L-methionine (SAM) and nicotinamide . Bisubstrate inhibitor 78 is selective for NNMT over histone-lysine N-methytransferase NSD2 and protein arginine methyltransferase 1 (PRMT1; IC50s = >50 μM for both). It reduces levels of 1-methylnicotinamide in, and inhibits proliferation of, HSC-2 oral cancer cells when used at a concentration of 100 μM.This compound is unstable in powder form and other related salt forms are recommended.

NNMTi (5-Amino-1-methylquinolinium) is a substrate site-targeting, selective nicotinamide N-methyltransferase (NNMT) inhibitor (IC50 = 1.2 μM; 50 μM SAM, 100 μM NCA) that reduces 3T3-L1 lipogenesis (EC50 = 30μM) and adipocytes 1-methylnicotinamide level (EC50 = 2.3 μM) without affecting related methyltransferases & enzymes in the NAD+ salvage pathway

JBSNF-000028 TFA, a nicotinamide N-methyltransferase (NNMT) inhibitor, exhibits oral activity with inhibitory concentration 50 (IC50) values of 0.033 μM, 0.19 μM, and 0.21 μM for human NNMT (hNNMT), monkey NNMT (mkNNMT), and mouse NNMT (mNNMT) respectively. It is applicable in metabolic disorder research [1].

MS2734 is a novel Bisubstrate Inhibitor of Nicotinamide N-Methyltransferase (NNMT).

LL320 is a selective inhibitor of NNMT, showing a K i,app of 6.8 nM, and interacts with RNMT, DPH5, and SAHH [1].

JBSNF-000028 hydrochloride is a potent inhibitor of nicotinamide N-methyltransferase (NNMT) with IC50 values of 0.033 μM for human NNMT (hNNMT), 0.19 μM for monkey NNMT (mkNNMT), and 0.21 μM for mouse NNMT (mNNMT). This orally active compound is utilized in the study of metabolic disorders [1].

JBSNF-000028 is an orally active inhibitor of nicotinamide N-methyltransferase (NNMT), with inhibitory concentration (IC50) values of 0.033 µM for human NNMT (hNNMT), 0.19 µM for monkey NNMT (mkNNMT), and 0.21 µM for mouse NNMT (mNNMT). This compound may be utilized in the study of metabolic disorders [1].